Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.55 |
| ▸ | DHFR | P00374 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12642514 | 0.83 | SCN9A (0.58) | ALOX5APFEN1 | |
| SCHEMBL29629017 | 0.78 | HTR7 (0.64) | ALDH1A1HTR7GAA | |
| SCHEMBL26556078 | 0.78 | HTR7 (0.64) | ALDH1A1HTR7GAA | |
| SCHEMBL31295947 | 0.78 | DYRK1A (0.69) | DYRK1AALDH1A1NPC1RAB9AADORA2A | |
| SCHEMBL3952084 | 0.77 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1DYRK1AALDH1A1NPC1 | |
| SCHEMBL7711745 | 0.77 | HSD17B10 (0.54) | HSP90AA1HSP90AB1DHFRALDH1A1ALOX5AP | |
| SCHEMBL1388381 | 0.76 | DYRK1A (0.66) | DHFRDYRK1AALDH1A1NPC1RAB9A | |
| SCHEMBL27702335 | 0.76 | BACE1 (0.49) | DHFRALOX5APFEN1ADORA1MAP4K4 | |
| SCHEMBL1039794 | 0.74 | HTR7 (0.55) | DHFRALDH1A1ALOX5APFEN1HTR7 | |
| SCHEMBL11645510 | 0.73 | ADORA2A (0.79) | HSP90AA1HSP90AB1DYRK1AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738710-B2 | Method of treating a patient for pain by administering an anti-ion channel antibody | UCB BIOPHARMA SPRL (BE) | 2017-08-22 | — | — | US | disclosed |
| US-20160222107-A1 | METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB BIOPHARMA SPRL (BE) | 2016-08-04 | — | — | US | disclosed |
| US-9266953-B2 | Methods of treating pain using function modifying NAv1.7 antibodies | UCB BIOPHARMA SPRL (BE) | 2016-02-23 | — | — | US | disclosed |
| US-20150232553-A1 | FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB PHARMA S.A. (BE) | 2015-08-20 | — | — | US | disclosed |
| US-20150203571-A1 | ANTIBODIES TO ION CHANNELS | UCB BIOPHARMA SPRL (BE) | 2015-07-23 | — | — | US | disclosed |
| US-8986954-B2 | DNA encoding function modifying Nav1.7 antibodies | UCB PHARMA S.A. (BE) | 2015-03-24 | — | — | US | disclosed |
| US-8926977-B2 | Antibodies to the E1 extracellular loop of ion channels | UCB PHARMA S.A. (BE) | 2015-01-06 | — | — | US | disclosed |
| US-20140342406-A1 | DNA ENCODING FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB PHARMA S.A. (BE) | 2014-11-20 | — | — | US | disclosed |
| US-8734798-B2 | Function modifying NAv 1.7 antibodies | UCB PHARMA S.A. (BE) | 2014-05-27 | — | — | US | disclosed |
| US-20120259096-A1 | ANTIBODIES TO ION CHANNELS | UCB PHARMA S.A. (BE) | 2012-10-11 | — | — | US | disclosed |
| US-20110135662-A1 | FUNCTION MODIFYING NAv 1.7 ANTIBODIES | UCB BIOPHARMA SPRL (BE) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259096-A1 | ANTIBODIES TO ION CHANNELS | SCN1A, KCNAB1, KCNMA1 | HSP90AA1 1729/4885HSP90AB1 1414/4885DHFR 3294/4885 |
| US-20110135662-A1 | FUNCTION MODIFYING NAv 1.7 ANTIBODIES | SCN7A, SCN1A, SCN5A | HSP90AA1 2598/4885HSP90AB1 1918/4885DHFR 4541/4885 |
| US-20150203571-A1 | ANTIBODIES TO ION CHANNELS | SCN1A, KCNAB1, KCNMA1 | HSP90AA1 1729/4885HSP90AB1 1414/4885DHFR 3294/4885 |
| US-20160222107-A1 | METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES | SCN7A, SCN3A, SCN1A | HSP90AA1 1912/4885HSP90AB1 1324/4885DHFR 3480/4885 |
| US-20150232553-A1 | FUNCTION MODIFYING NAv1.7 ANTIBODIES | SCN7A, SCN1A, SCN5A | HSP90AA1 2425/4885HSP90AB1 1833/4885DHFR 4342/4885 |
| US-20140342406-A1 | DNA ENCODING FUNCTION MODIFYING NAv1.7 ANTIBODIES | SCN7A, SCN1A, SCN8A | HSP90AA1 1733/4885HSP90AB1 1460/4885DHFR 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.